PD-1/PD-L1 (programmed cell death-1/programmed cell death-ligand 1) inhibitors, known as a kind of immune checkpoint inhibitors (ICIs), have revolutionized the paradigm of tumor therapy (1). This evidence concerns the gene PDCD1 and neoplasm.